What question did this study set out to answer?

The research aims to explore the effectiveness of PP2A activators in preventing relapse of glioblastoma after standard treatments.

March 25, 2026Cancer Research

Abstract B023: Targeting therapy induced senescence with small molecule Protein Phosphatase 2A (PP2A) activators to prevent glioblastoma relapse after first line treatment

View Full Paper

Ask AI

Bookmark

Authors

JOJohana T. OhlmeyerPrinceton Satellite Systems (United States)MSMuhammad SherazPrinceton Satellite Systems (United States)EBElizabeth A. BeierleChildren's of Alabama

Discussion

Member takes

Implication

This abstract demonstrates the potential of PP2A activators to prevent relapse in glioblastoma after first-line therapy, suggesting new treatment pathways.

Key Points

The research aims to explore the effectiveness of PP2A activators in preventing relapse of glioblastoma after standard treatments.
In vitro experiments with glioblastoma cells treated with temozolomide to induce senescence.
Application of the PP2A activator ATUX-1215 to assess its senolytic effects.
Evaluation of apoptosis via caspase-3/7 induction and SASP protein expression levels.
ATUX-1215 induces apoptosis in glioblastoma cells previously treated with temozolomide.
Reduction of senescence-associated secretory phenotype proteins, like CCL2 and PAI-1, in treated cells.
PP2A activation shows potential to mitigate tumor cell relapse in therapy-induced senescence.

Cite This Study

Ohlmeyer et al. (2026) studied this question.

synapsesocial.com/papers/69c37acab34aaaeb1a67ca9b https://doi.org/10.1158/1538-7445.brain26-b023

View Full Paper

Ask AI

Bookmark

Implication

This abstract demonstrates the potential of PP2A activators to prevent relapse in glioblastoma after first-line therapy, suggesting new treatment pathways.

Abstract B023: Targeting therapy induced senescence with small molecule Protein Phosphatase 2A (PP2A) activators to prevent glioblastoma relapse after first line treatment

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract B023: Targeting therapy induced senescence with small molecule Protein Phosphatase 2A (PP2A) activators to prevent glioblastoma relapse after first line treatment

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider